Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RPH-075 vs Keytruda in Unresectable or Metastatic Skin Melanoma
NCT06320353Phase 3Completed
- Sponsor
- R-Pharm
- Start
- Sep 2023
- Primary completion
- Aug 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of pembrolizumab in melanoma, sponsored by R-Pharm. Started Sep 2023; status: completed.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT06320353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06320353.